Skip to main content
Grant Details

Grant Number: 5R01CA242742-04 Interpret this number
Primary Investigator: Gonzalez, Brian
Organization: H. Lee Moffitt Cancer Ctr & Res Inst
Project Title: Identifying and Reducing Disparities in Patient-Reported Outcomes Among African American Prostate Cancer Survivors
Fiscal Year: 2023


PROJECT SUMMARY/ABSTRACT We propose a project to reduce morbidity as related to health disparities in prostate cancer survivors by identifying disparities in symptom burden and their contributors among African American prostate cancer survivors. The limited research reported that patient-reported quality of life outcomes are worse in African American compared to White prostate cancer survivors. Most importantly, other critically important symptom burden outcomes are largely understudied and overlooked in minorities. Previous research suggests African American prostate cancer survivors likely experience significant symptom burden for outcomes that are avoidable or treatable. The proposed project will address these critical public health concerns in the growing population of African American prostate cancer survivors.! This project aims to 1) Compare symptom burden between African American and White prostate cancer survivors, 2) Identify multilevel modifiable risk factors for worse symptom burden among both African American and White prostate cancer survivors, such as cultural, health behavior-related, psychosocial, and racial discrimination factors, and 3) Identify multilevel non-modifiable risk factors for worse symptom burden, such as genetic, clinical, treatment-related, and demographic factors. The risk factors we will study are informed by an adapted multilevel contextual model examining the levels of the person, social environment, and healthcare system.! This will be among the first and most comprehensive studies we are aware of to compare symptom burden between African American and White prostate cancer survivors. It will be the first we are aware of to identify modifiable and non-modifiable risk factors for worse symptom burden. These risk factor data will allow us to develop targeted interventions and identify high-risk individuals for monitoring and early intervention. In summary, this project's focus on identifying disparities and their risk factors supports the Healthy People 2020 goals of eliminating health disparities and improving quality of life in cancer survivors.


Sociocultural factors associated with physical activity in Black prostate cancer survivors.
Authors: Buro A.W. , Carson T.L. , Small B.J. , Fan W. , Oswald L.B. , Jim H.S.L. , Salas E. , Zambrano K. , Bryant C. , Yamoah K. , et al. .
Source: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023-07-22; 31(8), p. 482.
EPub date: 2023-07-22.
PMID: 37479918
Related Citations

Recruiting African American Prostate Cancer Survivors for a Population-based Biobank Study.
Authors: Li X. , Roy S. , Damonte J. , Park H.Y. , Hoogland A.I. , Jamison K. , Komrokji K.R. , Yeo C.D. , Kim Y. , Dhillon J. , et al. .
Source: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2023-06-01; 32(6), p. 768-775.
PMID: 36958853
Related Citations

"I Beat Cancer to Feel Sick:" Qualitative Experiences of Sleep Disturbance in Black Breast Cancer Survivors and Recommendations for Culturally Targeted Sleep Interventions.
Authors: Geiss C. , Chavez M.N. , Oswald L.B. , Ketcher D. , Reblin M. , Bandera E.V. , Savard J. , Zhou E.S. , Fox R.S. , Jim H.S.L. , et al. .
Source: Annals of behavioral medicine : a publication of the Society of Behavioral Medicine, 2022-11-05; 56(11), p. 1110-1115.
PMID: 35759312
Related Citations

Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
Authors: Gonzalez B.D. , Eisel S.L. , Bowles K.E. , Hoogland A.I. , James B.W. , Small B.J. , Sharpe S. , Hyland K.A. , Bulls H.W. , Christy S.M. , et al. .
Source: Journal of the National Cancer Institute, 2022-06-13; 114(6), p. 808-818.
PMID: 34508604
Related Citations

Back to Top